You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
First the news: Glen Tullman, currently the CEO Transcarent, has a new, roughly $100 million venture fund, called 62 Ventures. The plan, he told me, is to use the new fund to invest in startups that fall outside the strict digital health focus of his well-known fund 7wireVentures. Among his interests will be startups from India, which Tullman called his “home away from home as a country” and where he sees great opportunity. 62 Ventures will also invest U.S.-based companies and aims to write checks between $1 million and $10 million. The fund has already invested in BridgeHealthAI, a startup aimed at “simplifying health and social benefits navigation” for people experiencing health disparities; Khyaal, a “super app” for seniors in India; and Loop Health, a health insurance and integrated care company in India.
On new AI features for Transcarent
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect